Abstract Number: 2082 • 2013 ACR/ARHP Annual Meeting
Interferon-Regulated Chemokine and Innate Cytokine Scores Identify Refractory Myositis Patients That Respond Better To Rtuximab Therapy
Background/Purpose: Serum cytokines play an important role in the pathogenesis of myositis by initiating and perpetuating various cellular and humoral autoimmune processes. The aim of…Abstract Number: 2083 • 2013 ACR/ARHP Annual Meeting
Environmental Factors Associated With Disease Flare In Juvenile and Adult Dermatomyositis
Background/Purpose: To assess environmental factors in relationship to increased disease activity (flare) in juvenile and adult dermatomyositis (DM). Methods: An online survey was conducted for…Abstract Number: 2084 • 2013 ACR/ARHP Annual Meeting
Increasing Incidence Of Immune Mediated Necrotizing Myopathy In A Single Center
Background/Purpose: Immune mediated necrotizing myopathy (IMNM), characterized histologically by predominant myofiber necrosis with minimal or no inflammatory infiltrate and clinically by response to immunosuppressive therapy,…Abstract Number: 2085 • 2013 ACR/ARHP Annual Meeting
Identification Of Clinical Features and Risk Factors Associated With Calcinosis In Adult Patients With Dermatomyositis
Background/Purpose: Prior studies have estimated that 20% of adult dermatomyositis (DM) patients suffer from calcinosis. Although calcinosis is related to persistent disease activity, poor treatment…Abstract Number: 2086 • 2013 ACR/ARHP Annual Meeting
Defining The Prevalence and Associated Risk Factors For Calcinosis In Adult Dermatomyositis Patients
Background/Purpose: Calcinosis is known to be associated with junvenile dermatomyositis, but the prevalence and risk factors associated with the development of calcinosis in adult dermatomyositis…Abstract Number: 2087 • 2013 ACR/ARHP Annual Meeting
Utility and Reliability Of Digital Nailfold Capillaroscopy In Children With Juvenile Dermatomyositis: Three Methods
Background/Purpose: Nailfold Capillaroscopy (NFC) is a non-invasive assessment of the nailfold area of the fingers which aids in the diagnosis of Juvenile Dermatomyositis (JDM) by…Abstract Number: 2088 • 2013 ACR/ARHP Annual Meeting
The Percentage Of Th17 Cells Correlates with the Expression Of Microrna-206 In Patients With Dermatomyositis
Background/Purpose: DM (dermatomyositis) is a subtype of inflammatory myopathies，which is a rare autoimmune disease of skeletal muscle. Although the pathogenic mechanism of DM is still…Abstract Number: 2049 • 2013 ACR/ARHP Annual Meeting
Comparison Of Corticosteroid Plus Lidocaine Or Lidocaine Alone In Patients Receiving Celecoxib For The Treatment Of Acute Shoulder Or Trochanteric Bursitis: A Randomized, Double-Blind, Placebo Controlled Trial
Background/Purpose: Bursitis is a self-limiting disorder in the majority of patients and typically responds to conservative measures. However, corticosteroid injections may be necessary in recurrent…Abstract Number: 2050 • 2013 ACR/ARHP Annual Meeting
Arthralgia Occurring Under Aromatase Inhibitor Treatment For Breast Cancer. A Prospective Study
Background/Purpose: Treatment with third generation aromatase inhibitors (AI) is associated with occurrence of arthralgia, with an incidence ranging from 25 to 45 %. In these…Abstract Number: 2051 • 2013 ACR/ARHP Annual Meeting
Characteristics and Comparison Of Patients With Cystic Fibrosis With and Without Arthritis
Background/Purpose: Cystic Fibrosis (CF) is a common genetic mutation in Caucasian populations. Many patients have musculoskeletal complaints and 12% develop arthritis, including CF arthropathy (CFA),…Abstract Number: 2052 • 2013 ACR/ARHP Annual Meeting
The Prevalence and Pattern Of Self Reported Joint Symptoms In Cystic Fibrosis
Background/Purpose: Arthritis in cystic fibrosis (CF) can be very incapacitating, and it is mainly of three types: CF arthritis, hypertrophic osteoarthropathy, and arthritis due to…Abstract Number: 2053 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Intermittent Intra-Venous Cyclophosphamide and Cyclosporin A Combination Therapy For Rapidly Progressive Interstitial Lung Disease With Dermatomyositis Associated With Anti-Melanoma Differentiation-Associated Gene 5 Autoantibody Titer
Background/Purpose: Anti-Melanoma Differentiation-Associated Gene 5 (MDA5) autoantibody is present specifically in patients with dermatomyositis (DM), especially those with few or no muscle manifestations (clinically amyopathic…Abstract Number: 2054 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Low-Intensity Resistance Training Combined With Vascular Occlusion In Polymyositis and Dermatomyositis
Background/Purpose: Previous studies have demonstrated that low-intensity resistance training combined with vascular occlusion (VO) improves muscle strength to the magnitude of traditional high-intensity resistance training…Abstract Number: 2055 • 2013 ACR/ARHP Annual Meeting
Killer T Cell Inhibition By CD226 Blockade For Treatment Of Inflammatory Myopathy
Background/Purpose: Current treatment strategy of polymyositis/dermatomyositis calls for administration of high dose glucocorticoids and additional immunosupressants when necessary. These options are based largely on successful…Abstract Number: 2056 • 2013 ACR/ARHP Annual Meeting
Use Of Biologics In Polymyositis and Dermatomyositis – A National Register Study
Background/Purpose: Biologics have been used off-label in treatment of refractory polymyositis (PM) and dermatomyositis (DM). In this study we aimed to describe the use of…
ACR Meeting Abstracts